Latest Hematological malignancy Stories
WHITE PLAINS, N.Y., Dec. 22, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Team In Training (TNT), the world's biggest and most successful charity endurance sports training program, has been voted Best Charity Training Program in the 2011 BEST of Competitor poll. The winners were chosen by votes from Competitor magazine readers. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) TNT won this title in all eight regions where Competitor is...
Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method yet for imaging a form of Non-Hodgkin’s disease called mantle cell lymphoma, a relatively rare and devastating blood cancer. The pilot study is published in the December issue of The Journal of Nuclear Medicine. Lymphoma is the term used for an array of cancers that affect blood cells and the lymphatic system. These cancers are typically...
Results may aid treatment decisions in chronic lymphocytic leukemia The most comprehensive search to date of DNA abnormalities in chronic lymphocytic leukemia (CLL) has unearthed several new altered genes that drive this common blood cancer, a finding that could potentially help doctors predict whether an individual patient's disease will progress rapidly or remain indolent for years, say scientists from Dana-Farber Cancer Institute and the Broad Institute. Using powerful...
SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center. Jakubowiak will present final results of the phase I-II study on Dec. 12, 2011, at the American...
Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients’ lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology. “While recent discoveries...
SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from an oncology pipeline molecule today at the 53rd Annual Meeting of the American Society of Hematology (ASH). At the meeting, Lilly Oncology presented Phase I data from the investigational therapy LY2784544, a small-molecule Janus kinase 2 (JAK2) inhibitor, in development for the treatment of certain types of myeloproliferative neoplasms (MPNs), a group of blood cancers[1] characterized by...
SAN DIEGO, Dec. 10, 2011 /PRNewswire-USNewswire/ -- Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the...
Giving has never been easier… or less expensive. Anytime between now and December 31, 2011, with a simple click on the PlanningFamily.com “Like†button at http://www.facebook.com/planningfamily , PlanningFamily.com will donate $1 to battle pediatric blood cancers to The Leukemia & Lymphoma Society (LLS). 100% of Donations Directly Benefiting The Fight Against Pediatric Blood Cancer. Costa Mesa, CA (PRWEB) December 09, 2011 Giving has never been easier… or less...
NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that two studies of SL-401, a clinical stage therapeutic being developed in patients with myeloid malignancies, have also demonstrated preclinical activity against a variety of lymphoid malignancies and have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, CA from December 10-13, 2011. One study demonstrates...
WHITE PLAINS, N.Y., Dec. 5, 2011 /PRNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in San Diego December 10-13, 2011. <font size="2" face="Arial">(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO )</font> New discoveries in immunotherapies, blood cancer stem cells, genomics and molecularly targeted therapies will be among the...
